Pacira BioSciences' Beginning Cash Balance rose 21.63% to $300.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.0 million, marking a year-over-year increase of 148.15%. This contributed to the annual value of $153.3 million for FY2024, which is 47.21% up from last year.
According to the latest figures from Q3 2025, Pacira BioSciences' Beginning Cash Balance is $300.5 million, which was up 5.95% from $283.6 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Beginning Cash Balance registered a high of $585.6 million during Q1 2022, and its lowest value of $35.5 million during Q2 2023.
In the last 3 years, Pacira BioSciences' Beginning Cash Balance had a median value of $184.1 million in 2024 and averaged $183.3 million.
As far as peak fluctuations go, Pacira BioSciences' Beginning Cash Balance skyrocketed by 485.83% in 2022, and later crashed by 84.32% in 2023.
Pacira BioSciences' Beginning Cash Balance (MRQ) stood at $134.0 million in 2021, then dropped by 18.36% to $109.4 million in 2022, then dropped by 9.42% to $99.1 million in 2023, then skyrocketed by 148.15% to $246.0 million in 2024, then rose by 22.17% to $300.5 million in 2025.
Its Beginning Cash Balance stands at $300.5 million for Q3 2025, versus $283.6 million for Q2 2025 and $276.8 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value